Type of non Hodgkin's lymphoma-Follicular lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

Posted by on Jan 23, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of radiotherapy (RT) for the treatment of patients with indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that RT was highly effective with manageable side effects in these patients. Some background Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells...

Read More

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

Posted by on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients.  Some background B-NHL is a type of...

Read More

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Posted by on Oct 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The review aimed to assess chemotherapy-free treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL).   Some background Standard therapy for slow-growing non-Hodgkin lymphoma (NHL) such as FL and MZL involves immunochemotherapy (ICT). ICT combines immunotherapy and chemotherapy treatments. However, many patients...

Read More

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Posted by on Oct 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...

Read More

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the role of PET/CT scanning in the treatment of patients with recurrent or hard-to-treat B-cell non-Hodgkin’s lymphoma (NHL) after T-cell therapy. This study found that PET/CT scanning helped predict the effectiveness and side effects of treatment for these patients. Some background Chemoimmunotherapy...

Read More

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without...

Read More

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Posted by on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...

Read More

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...

Read More

Evaluating long-term effectiveness and safety of venetoclax patients with for non-Hodgkin lymphoma

Evaluating long-term effectiveness and safety of venetoclax patients with for non-Hodgkin lymphoma

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This early study looked at the long-term results of the targeted treatment venetoclax (Venclexta) for patients with relapsed non-Hodgkin lymphoma (NHL). It found that venetoclax is a safe and effective treatment and that some patients have a durable response. Some background NHL is a group of cancers of a type of white blood...

Read More

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Posted by on May 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety outcomes of copanlisib (Aliqopa) and rituximab (Rituxan) combination for the treatment of patients with relapsed indolent (painless) non-Hodgkin lymphoma (NHL). The data showed that this combination improved the outcomes of these patients with manageable side effects. Some background...

Read More

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors compared a high-dose radiation (24 Gy) in 12 parts with a low-dose radiation (4 Gy) in 2 parts in patients with slow-growing non-Hodgkin lymphomas (NHLs). The study found that the best radiotherapy dose for slow-growing NHLs is 24 Gy in 12 parts after a 5-year follow-up. Some background The current standard of care for...

Read More

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...

Read More